Innovus Pharmaceuticals, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 11/14/2016
Contact Info
  • 9171 Towne Centre Drive
  • Suite 440
  • San Diego, CA 92122

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0001411879
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. Not Available
Employees 8 a/o May 01, 2015
Company Officers/Contacts
Bassam Damaj, Ph D President, CEO, IR
Robert Hoffman CFO, EVP
Reuven Rubinson VP, Fin.
Randy Berholtz General Counsel
Company Directors
Henry Esber Chairman
Bassam Damaj, Ph D
Vivian Liu
Ziad Mirza
Service Providers
Accounting/Auditing Firm
EisnerAmper LLP
111 Wood Avenue South
Suite 600
Iselin, NJ, 08830-2700
United States
Hall & Company CPAs & Consultants, Inc.
111 Pacifica
Suite 300
Irvine, CA, 92618
United States
Securities Counsel
Weintraub Law Group PC
10085 Carroll Canyon Rd.
Suite 230
San Diego, CA, 92131
United States
Investor Relations Firm
Chesapeake Group
305 Washington Ave
Suite 100
Towson, MD, 21204
United States
Company History
  • Formerly=North Horizon, Inc. until 12-2011
INNV Security Details
Share Structure
Market Value1 $16,707,700 a/o Feb 24, 2017
Authorized Shares 150,000,000 a/o Sep 30, 2016
Outstanding Shares 106,080,636 a/o Nov 10, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 15,301,429 a/o Apr 12, 2016
Par Value 0.001
Transfer Agent(s) Verified by Transfer Agent
Interwest Transfer Co., Inc.
Shareholders of Record 545 a/o Apr 12, 2016
Short Selling Data
Short Interest 350,311 (-2.67%)
Jan 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security